• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

广义线性模型在危险函数参数建模中的应用

Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function.

机构信息

The University of Sheffield, Sheffield, UK.

The University of York, York, UK.

出版信息

Med Decis Making. 2019 Oct;39(7):867-878. doi: 10.1177/0272989X19873661. Epub 2019 Sep 26.

DOI:10.1177/0272989X19873661
PMID:31556792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6843612/
Abstract

Parametric modeling of survival data is important, and reimbursement decisions may depend on the selected distribution. Accurate predictions require sufficiently flexible models to describe adequately the temporal evolution of the hazard function. A rich class of models is available among the framework of generalized linear models (GLMs) and its extensions, but these models are rarely applied to survival data. This article describes the theoretical properties of these more flexible models and compares their performance to standard survival models in a reproducible case study. We describe how survival data may be analyzed with GLMs and their extensions: fractional polynomials, spline models, generalized additive models, generalized linear mixed (frailty) models, and dynamic survival models. For each, we provide a comparison of the strengths and limitations of these approaches. For the case study, we compare within-sample fit, the plausibility of extrapolations, and extrapolation performance based on data splitting. Viewing standard survival models as GLMs shows that many impose a restrictive assumption of linearity. For the case study, GLMs provided better within-sample fit and more plausible extrapolations. However, they did not improve extrapolation performance. We also provide guidance to aid in choosing between the different approaches based on GLMs and their extensions. The use of GLMs for parametric survival analysis can outperform standard parametric survival models, although the improvements were modest in our case study. This approach is currently seldom used. We provide guidance on both implementing these models and choosing between them. The reproducible case study will help to increase uptake of these models.

摘要

生存数据的参数建模很重要,而报销决策可能取决于所选的分布。准确的预测需要足够灵活的模型来充分描述危险函数的时间演变。广义线性模型 (GLM) 及其扩展框架中提供了丰富的模型类,但这些模型很少应用于生存数据。本文描述了这些更灵活模型的理论性质,并在可重现的案例研究中比较了它们与标准生存模型的性能。我们描述了如何使用 GLM 及其扩展(分数多项式、样条模型、广义加性模型、广义线性混合(脆弱性)模型和动态生存模型)来分析生存数据。对于每种方法,我们都提供了对这些方法的优缺点的比较。对于案例研究,我们比较了样本内拟合、外推的合理性以及基于数据分割的外推性能。将标准生存模型视为 GLM 表明,许多模型都强加了线性的限制性假设。对于案例研究,GLM 提供了更好的样本内拟合和更合理的外推。然而,它们并没有提高外推性能。我们还根据 GLM 及其扩展为不同方法的选择提供了指导。对于参数生存分析,GLM 的使用可以优于标准参数生存模型,尽管在我们的案例研究中改进是适度的。这种方法目前很少使用。我们提供了关于实施这些模型和选择它们之间的指导。可重现的案例研究将有助于提高这些模型的采用率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/6843612/92bb0cbf7f2f/10.1177_0272989X19873661-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/6843612/be19e9c73235/10.1177_0272989X19873661-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/6843612/bf91e25d1838/10.1177_0272989X19873661-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/6843612/92bb0cbf7f2f/10.1177_0272989X19873661-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/6843612/be19e9c73235/10.1177_0272989X19873661-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/6843612/bf91e25d1838/10.1177_0272989X19873661-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/6843612/92bb0cbf7f2f/10.1177_0272989X19873661-fig3.jpg

相似文献

1
Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function.广义线性模型在危险函数参数建模中的应用
Med Decis Making. 2019 Oct;39(7):867-878. doi: 10.1177/0272989X19873661. Epub 2019 Sep 26.
2
Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study.比较当前和新兴的生存数据外推实践模型:一项模拟研究和案例研究。
BMC Med Res Methodol. 2021 Nov 27;21(1):263. doi: 10.1186/s12874-021-01460-1.
3
The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study.具有治愈比例的数据的生存模型外推性能:一项模拟研究。
Value Health. 2021 Nov;24(11):1634-1642. doi: 10.1016/j.jval.2021.05.009. Epub 2021 Jul 28.
4
Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.动态和灵活的相对生存率外推生存模型:案例研究和模拟研究。
Med Decis Making. 2022 Oct;42(7):945-955. doi: 10.1177/0272989X221107649. Epub 2022 Jun 29.
5
Generalized nonlinearity in animal ecology: Research, review, and recommendations.动物生态学中的广义非线性:研究、综述与建议。
Ecol Evol. 2024 Jul 11;14(7):e11387. doi: 10.1002/ece3.11387. eCollection 2024 Jul.
6
Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.使用多次预先计划的数据切割评估免疫肿瘤学中的生存外推:辅助模型选择的经验教训。
BMC Med Res Methodol. 2020 May 6;20(1):103. doi: 10.1186/s12874-020-00997-x.
7
Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.使用标准参数模型和灵活参数样条模型外推生存曲线:在晚期癌症大型注册队列中的比较。
Med Decis Making. 2021 Feb;41(2):179-193. doi: 10.1177/0272989X20978958. Epub 2020 Dec 22.
8
General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden.癌症试验生存外推中的一般人群死亡率调整:探索在瑞典 HER2 阳性乳腺癌中的成本效益分析中的合理性和影响。
Med Decis Making. 2024 Oct;44(7):843-853. doi: 10.1177/0272989X241275969. Epub 2024 Sep 12.
9
Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.在两项晚期非小细胞肺癌(NSCLC)纳武单抗试验中,利用先进的灵活建模方法从早期随访数据进行生存外推并延长随访时间。
Med Decis Making. 2023 Jan;43(1):91-109. doi: 10.1177/0272989X221132257. Epub 2022 Oct 19.
10
Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.使用瑞典癌症登记处,通过标准参数模型和灵活参数样条模型在全因和相对生存框架内比较生存推断。
Med Decis Making. 2024 Apr;44(3):269-282. doi: 10.1177/0272989X241227230. Epub 2024 Feb 5.

引用本文的文献

1
Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study.难治性结直肠癌全身治疗的安全性、有效性和成本效益评估:一项系统评价与建模研究
Health Econ Rev. 2025 Apr 11;15(1):33. doi: 10.1186/s13561-025-00622-x.
2
Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma.替雷利珠单抗联合化疗一线治疗晚期胃癌或胃食管交界腺癌的最新成本效益分析
Front Oncol. 2024 Dec 16;14:1477722. doi: 10.3389/fonc.2024.1477722. eCollection 2024.
3

本文引用的文献

1
flexsurv: A Platform for Parametric Survival Modeling in R.flexsurv:R语言中用于参数生存建模的一个平台。
J Stat Softw. 2016 May 12;70. doi: 10.18637/jss.v070.i08.
2
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.在经济评估中对免疫肿瘤药物的生存结局进行建模:数据分析和外推的系统方法。
Pharmacoeconomics. 2017 Dec;35(12):1257-1270. doi: 10.1007/s40273-017-0558-5.
3
Extrapolation of Survival Data in Cost-effectiveness Analyses: The Need for Causal Clarity.
Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.
替雷利珠单抗联合化疗治疗中国晚期或转移性食管鳞癌患者的成本-效果分析。
Sci Rep. 2024 Jul 31;14(1):17734. doi: 10.1038/s41598-024-68399-3.
4
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.头孢地尔罗治疗严重需氧革兰氏阴性细菌感染:技术评估以提供一种新的订阅式支付模式。
Health Technol Assess. 2024 Jun;28(28):1-238. doi: 10.3310/YGWR4511.
5
The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.zolbetuximab 在 CLDN18.2 阳性胃或胃食管结合部腺癌中的成本效益。
Pharmacogenomics. 2024;25(5-6):249-257. doi: 10.1080/14622416.2024.2344438. Epub 2024 May 10.
6
Using Age-Specific Rates for Parametric Survival Function Estimation in Simulation Models.使用特定年龄的参数生存函数估计在仿真模型中。
Med Decis Making. 2024 May;44(4):359-364. doi: 10.1177/0272989X241232967. Epub 2024 Feb 25.
7
Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.索托拉西布对比多西他赛治疗美国和中国 KRAS p.G12C 突变型局部晚期或转移性非小细胞肺癌患者的成本效果分析:药物定价信息。
Medicine (Baltimore). 2023 Dec 15;102(50):e36387. doi: 10.1097/MD.0000000000036387.
8
Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.阿特珠单抗治疗不符合含铂化疗方案治疗条件的非小细胞肺癌患者的成本效果分析:英国医疗保健视角。
Front Public Health. 2023 Sep 29;11:1282374. doi: 10.3389/fpubh.2023.1282374. eCollection 2023.
9
Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.托瑞帕利单抗联合化疗与单纯化疗治疗晚期非小细胞肺癌患者的成本效益分析。
Front Pharmacol. 2023 Feb 14;14:1131219. doi: 10.3389/fphar.2023.1131219. eCollection 2023.
10
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.塞普鲁单抗联合化疗对比化疗治疗美国和中国广泛期小细胞肺癌患者的成本效果分析:为药物定价提供信息。
BioDrugs. 2023 May;37(3):421-432. doi: 10.1007/s40259-023-00586-6. Epub 2023 Feb 25.
成本效益分析中生存数据的外推:因果关系明确的必要性。
Med Decis Making. 2017 May;37(4):337-339. doi: 10.1177/0272989X17697019. Epub 2017 Mar 29.
4
Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.绝经后女性卵巢癌筛查的成本效益:基于模型的经济学评估
BMC Med. 2016 Dec 6;14(1):200. doi: 10.1186/s12916-016-0743-y.
5
Extrapolation of Survival Curves from Cancer Trials Using External Information.利用外部信息对癌症试验的生存曲线进行外推
Med Decis Making. 2017 May;37(4):353-366. doi: 10.1177/0272989X16670604. Epub 2016 Sep 29.
6
Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods.利用外部数据从随机试验推断生存率:方法综述
Med Decis Making. 2017 May;37(4):377-390. doi: 10.1177/0272989X16639900. Epub 2016 Jul 10.
7
A general framework for parametric survival analysis.参数生存分析的一般框架。
Stat Med. 2014 Dec 30;33(30):5280-97. doi: 10.1002/sim.6300. Epub 2014 Sep 15.
8
Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach.生存分析和时间事件临床试验数据经济评价的外推建模:一种替代方法。
Med Decis Making. 2014 Apr;34(3):343-51. doi: 10.1177/0272989X13497998. Epub 2013 Jul 30.
9
Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.生存分析在临床试验中的经济评估——利用患者水平数据进行外推:不一致性、局限性和实用指南。
Med Decis Making. 2013 Aug;33(6):743-54. doi: 10.1177/0272989X12472398. Epub 2013 Jan 22.
10
Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.健康经济评估中的生存模型:平衡拟合优度与简约性以改善预测
Int J Biostat. 2010;6(1):Article 34. doi: 10.2202/1557-4679.1269.